Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin
The primary focus of the CRL relates to the
“West and Assertio will work together to determine how best to address the CRL,” said
Long-acting cosyntropin is an alcohol-free formulation of a synthetic analogue of ACTH, a hormone secreted from the pituitary gland that is responsible for the stimulation of the adrenal cortex. Cosyntropin is composed of the first 24 of 39 amino acids of natural ACTH and retains the full steroidogenic activity of natural ACTH.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks related to regulatory approval and clinical development of long-acting cosyntropin, expectations regarding potential business opportunities and other risks outlined in the Company's public filings with the
Investor and Media Contact:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.